The inaugural competition surprisingly awarded two $100,000 grand prizes to address challenges in defining robust benchmarks for complex biology.

In this GEN webinar, our expert speakers will explore cutting-edge drug discovery techniques for target deconvolution and multiplex target discovery.

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

Gut-microbe–derived trimethylamine (TMA) blocks a key immune protein, reducing inflammation and improving blood-sugar control.

While House, Senate thwarted 40% cut to agency’s budget, about half of the largest recipients of agency grants saw cuts ...

For super-resolution microscopes, AI helps by restoring images from even noisy, low-fluorescence data. That capability helps ...

Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

We discuss studies in organoids, autism, and sarcopenia, Lundbeck’s decision to end its bid for Avadel and Protego’s fundraising round.

NeuMap, the first single‑cell atlas of neutrophils, reveals conserved functional hubs across health, infection, and cancer, reshaping immunity.

Mice lacking the extracellular matrix protein tenascin-C showed a reduced ability to repair muscular damage compared to controls.

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

With the advent of AI-powered protein design tools, protein-based therapeutics may no longer be constrained by the limits imposed by natural selection.